Conducting Airways in Lung Fibrosis (VACFI)

Idiopathic Pulmonary Fibrosis Clinical Trial

— VACFI  

Official title:

Conducting Airways in Lung Fibrosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01777373
• Other study ID #: P110902
• Secondary ID: N° IDRCB : 2012-
• Status: Completed
• Phase: N/A
• First received: October 2, 2012
• Last updated: April 9, 2015
• Start date: August 2012
• Est. completion date: February 2015

Study information

• Verified date: December 2014
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether extension of the conducting airways into the distal lung, or bronchiolization, occurs early in the course of Idiopathic Pulmonary Fibrosis, a disease wherein normal lung structures are destroyed and replaced by non-functional scar tissue.

Description:

Diffuse Interstitial Pneumonias are a heterogeneous group of chronic respiratory diseases. Idiopathic Pulmonary Fibrosis, one of such diseases, is characterized by lesions of the conducting airways including extension of bronchioles towards the distal lung, or bronchiolization of the distal lung. Such lesions are traditionally referred to as "traction bronchiectasis" although no evidence supports a cause-and-effect relationship between alveolar fibrosis and airway lesions. Another feature of IPF is chronic, invalidating dry cough. Our hypothesis is that IPF is characterized by early increases in the volume of conducting airways, that such changes correlate with cough, and that airway changes are in direct relation with airway fibrosis. The primary aim of this study is to demonstrate increased anatomical dead space (VD), a surrogate for conducting airway volume, in patients with moderate (or early) IPF, in comparison with subjects without any respiratory disease ("non-DIP controls"). The secondary aims are : To show that VD is increased in patients with IPF in comparison with patients with other DIPs ("DIP controls"), to show that in patients with IPF increased VD does not correlate with indices of alveolar fibrosis, and to show associations between increased VD and cough and other respiratory symptoms in patients with IPF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 141
• Est. completion date: February 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

IPF :

INCLUSION CRITERIA

1. Age 18-85 years

2. IPF diagnosed according to ATS/ERS/JRS/ALAT criteria

3. Patient gave informed consent

NON INCLUSION CRITERIA

1. Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema, tuberculosis sequelae, prior lung surgery

2. Obstructive ventilatory disorder

3. Counterindication to pulmonary function testing

4. Women : Pregnancy or milking

5. Lack of health insurance

Controls :

INCLUSION CRITERIA

1. Volunteers aged 18-85 years, free of any respiratory disease

2. Volunteer gave informed consent

Secondary EXCLUSION CRITERIA Abnormal PFT : Total lung capacity or FEV1/VC ratio < Lower Limit of Normal

Non-IPF ILD :

INCLUSION CRITERIA

1. Age 18-85 years

2. Radiological interstitial pneumonia, on 2 tests performed >3 months apart

3. PINS histology OR sarcoidosis histology OR clinical diagnosis of drug-induced lung disease OR diagnosis of auto-immune disease

4. Patient gave informed consent

NON INCLUSION CRITERIA

1. Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema, tuberculosis sequelae, prior lung surgery

2. Obstructive ventilatory disorder

3. Counterindication to pulmonary function testing

4. Women : Pregnancy or milking

5. Lack of health insurance

Uncharacterized ILD :

INCLUSION CRITERIA

1. Age 18-85 years

2. Radiological interstitial pneumonia, on 2 tests performed >3 months apart

3. Patient gave informed consent

NON INCLUSION CRITERIA

1. Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema, tuberculosis sequelae, prior lung surgery

2. Obstructive ventilatory disorder

3. Counterindication to pulmonary function testing

4. Women : Pregnancy or milking

5. Lack of health insurance

Secondary EXCLUSION CRITERIA Final diagnosis other than either IPF or non-IPF interstitial pneumonia.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
France	Hôpital Bichat	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fowler dead space	Conducting airway volume is determined by Fowler's method from volumetric capnography data	1 day	No
Secondary	Bohr anatomic dead space	Bohr anatomic dead space is determined from capnography and spirometry data.	1 day	No